Key result
Finerenone reduces CV mortality, HF hospitalizations, and renal progression in DKD and HFmrEF/HFpEF.
Why the study?
Conventional steroidal MRAs reduce morbidity and mortality in HFrEF, but their broader clinical utility is constrained by anti-androgenic sequelae and therapy-limiting hyperkalemia. This review evaluates the nonsteroidal selective MRA finerenone, its pharmacological profile, landmark clinical trials, and its role across cardiovascular disease and heart failure.
Does finerenone reduce cardiovascular mortality, hospitalizations for worsening heart failure, and renal progression in patients with diabetic kidney disease and HFmrEF/HFpEF?
Does finerenone reduce cardiovascular mortality, hospitalizations for worsening heart failure, and renal progression in patients with diabetic kidney disease and HFmrEF/HFpEF?
This narrative review highlights the role of finerenone in attenuating cardiovascular mortality, heart failure hospitalizations, and renal progression across diabetic kidney disease and HFmrEF/HFpEF while minimizing severe hyperkalemia and avoiding anti-androgenic side effects.
Answers are grounded in this paper and cite their sources.
Supports finerenone in DKD and HFmrEF/HFpEF; leaves open head-to-head trials versus steroidal MRAs and real-world durability.
Pathological hyperactivation of the mineralocorticoid receptor (MR) serves as a primary driver of adverse cardiovascular outcomes, orchestrating myocardial fibrosis, microvascular endothelial inflammation, electrical instability, and progressive left ventricular remodeling. Although conventional steroidal MR antagonists (MRAs)—predominantly spironolactone and eplerenone—have established morbidity and mortality reductions in heart failure with reduced ejection fraction (HFrEF), their broader clinical utility remains constrained by anti-androgenic sequelae and therapy-limiting hyperkalemia. Finerenone represents a first-in-class, nonsteroidal selective MRA characterized by a unique dihydropyridine-derived chemical structure that confers high-affinity, balanced cardiorenal receptor blockade without steroid-axis cross-reactivity. Pivotal phase 3 clinical trials, including FIDELIO-DKD, FIGARO-DKD, the pooled FIDELITY analysis, and the FINEARTS-HF trial, have substantiated that finerenone significantly attenuates cardiovascular mortality, hospitalizations for worsening heart failure, and renal progression across diabetic kidney disease and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). With an equimolar cardiorenal tissue distribution, short terminal half-life, and complete absence of active circulating metabolites, finerenone minimizes severe hyperkalemic episodes and eliminates anti-androgenic side effects. This narrative review evaluates MR-mediated pathophysiology, the structural and pharmacokinetic characteristics of finerenone, landmark clinical trials, practical potassium surveillance protocols, and its transformative role in contemporary cardiovascular therapeutics.
No takes yet. Share an insight, caveat, or question.
C et al. (2026) conducted a review in Cardiovascular disease, diabetic kidney disease, and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Finerenone vs. Conventional steroidal mineralocorticoid receptor antagonists (spironolactone, eplerenone) or placebo was evaluated on Cardiovascular mortality, hospitalizations for worsening heart failure, and renal progression. Finerenone attenuates cardiovascular mortality, heart failure hospitalizations, and renal progression across diabetic kidney disease and HFmrEF/HFpEF in phase 3 clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: